Anticorps Polyclonal de lapin anti-DCBLD2

• Phare
• Validé par KD/KO

DCBLD2 Polyclonal Antibody for IP, WB, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain et plus (1)

Applications

WB, IP, IHC, ELISA

Conjugaison

Non conjugué

Publications

3

N° de cat : 13168-1-AP

Synonymes

CLCP1, DCBLD2, ESDN

---

Galerie de données de validation

• 

  WB analysis using 13168-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 13168-1-AP (DCBLD2 antibody) at dilution of 1:1500 incubated at room temperature for 1.5 hours.

• 

  WB analysis of human liver using 13168-1-AP

  human liver tissue were subjected to SDS PAGE followed by western blot with 13168-1-AP (DCBLD2 antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.

• 

  WB analysis of human brain using 13168-1-AP

  human brain tissue were subjected to SDS PAGE followed by western blot with 13168-1-AP (DCBLD2 antibody) at dilution of 1:1500 incubated at room temperature for 1.5 hours.

• 

  IP experiment of U2OS using 13168-1-AP

  IP result of anti-DCBLD2(IP:13168-1-AP, 4ug; Detection:13168-1-AP 1:1000) with U2OS cells lysate 440 ug.

---

Applications testées

• Résultats positifs en WB: cellules MKN-45, cellules U2OS, tissu cérébral humain, tissu hépatique humain
• Résultats positifs en IP: cellules U2OS,

Dilution recommandée

• Western Blot (WB): WB : 1:500-1:3000
• Immunoprécipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• KD/KO: See 1 publications below
• WB: See 3 publications below
• IHC: See 1 publications below

Informations sur le produit

13168-1-AP cible DCBLD2 dans les applications de WB, IP, IHC, ELISA et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Réactivité citée: Humain, souris
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: DCBLD2 Protéine recombinante Ag3821
• Nom complet: discoidin, CUB and LCCL domain containing 2
• Masse moléculaire calculée: 775 aa, 89 kDa
• Poids moléculaire observé: 93 kDa, 127 kDa
• Numéro d’acquisition GenBank: BC029658
• Symbole du gène: DCBLD2
• Identification du gène (NCBI): 131566
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

DCBLD2, also known as ESDN or CLCP1, was first identified from human coronary arterial cells by a signal sequence trap method. DCBLD2 regulates proliferation, migration, and invasion in various tumors, including glioma, hypopharyngeal squamous cell carcinoma, and myxofibrosarcoma. The human DCBLD2 protein has a predicted molecular mass of ∼80 kDa based on its amino acid sequence, although it regularly displays an effective molecular mass of ∼130 kDa via SDS-PAGE (PMID: 30902898).

Publications

Species	Application	Title
human	WB	Environ Toxicol; Comprehensive analyses and experimental verification of NETs and an EMT gene signature for prognostic prediction, immunotherapy, and chemotherapy in pancreatic adenocarcinoma; Authors - Jing Zhang ; KD Validated
human	WB,IHC	Am J Cancer Res; In silico development and in vitro validation of a novel five-gene signature for prognostic prediction in colon cancer; Authors - Qiankun Zhu
mouse	WB	Aging (Albany NY); Plumbagin has an inhibitory effect on the growth of TSCC PDX model and it enhances the anticancer efficacy of cisplatin; Authors - Yuqi Xin